Nexera-e Comprehensive LCxLC System – Exponential chromatography
Shimadzu has introduced its new Nexera-e comprehensive LCxLC system. The instrument combines two orthogonal separation modes to separate even the most complex mixtures, such as structural analogues in food and natural extracts, in just one analysis. The "e" implies exponentially better chromatography due to an exponential increase in peak capacity and resolution, enabling the analysis of multiple compounds and identification of chemical class patterns in a single chromatogram. One injection and sample preparation instead of several approaches underlines the system's efficiency.
The ultra-fast LCMS-2020 single quadrupole LC-MS detector provides selective, highly sensitive analysis of trace components. The ChromSquare V2 data analysis software for intuitive 2D data processing and visualization completes the package.
For more information please visit www.shimadzu.eu
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
